RECRUITING

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Description

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Conditions

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Ovarian Clear Cell AdenocarcinomaChondrosarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Recurrent Ovarian High Grade Serous AdenocarcinomaRefractory Endometrial CarcinomaRefractory Head and Neck Squamous Cell CarcinomaRefractory MelanomaRefractory Ovarian Clear Cell AdenocarcinomaRefractory Ovarian High Grade Serous AdenocarcinomaStage III Ovarian Cancer AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8
Talk to us

Related Conditions:

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Ovarian Clear Cell AdenocarcinomaChondrosarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Recurrent Ovarian High Grade Serous AdenocarcinomaRefractory Endometrial CarcinomaRefractory Head and Neck Squamous Cell CarcinomaRefractory MelanomaRefractory Ovarian Clear Cell AdenocarcinomaRefractory Ovarian High Grade Serous AdenocarcinomaStage III Ovarian Cancer AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Uterine Corpus Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8

Study Overview

On this page

Study Details

Study overview

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Condition
Advanced Endometrial Carcinoma
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    M.D. Anderson Cancer Center,

    Timothy A Yap, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

    Study Record Dates

    2026-05-29